摘要
目的探讨伊贝沙坦治疗充血性心力衰竭(CHF)的临床疗效。方法CHF患者120例随即分为治疗组和对照组。在常规治疗方法基础上,治疗组64例给予伊贝沙坦(Irb)150mg/d,疗程8周。观察治疗前后两组患者的临床症状,超声心动图记录心功能变化及不良反应。结果两组治疗前后相比,左室射血分数(LVEF)、每搏量(SV)、心脏指数(CI)均有显著改善(P<0.01)。结论伊贝沙坦治疗CHF是安全可靠的,且能增强疗效。
Objective To observe the clinical effect of Irbesartan to treat CHF, Methods 120 patients with CHF were randomly divided into the treatment group and the contrast group. According to the common dosage,64 patients in the treatment group took irbesartan 150mg/d, during the period of 8 weeks, while 56 patients in other group took placeboes during the same period. Observe clinical symptoms, LVEF, SV, CI, Ang Ⅱ , ACD, PRA, ANP and adverse reaction from the two groups above. Results In contrast with those before the treatment, the patients in the treatment group had a significant improvement on LVEF,SV, CI. Conclusion Irbesartan is secure for treating CHF and can increase therapeutic effect.
出处
《中国基层医药》
CAS
2006年第4期603-604,共2页
Chinese Journal of Primary Medicine and Pharmacy
